Clinical DevelopmentTuspetinib is shaping up to be a welcome addition to first-line advanced AML.
Mechanism Of ActionTUS's mechanism of action provides a real opportunity to improve upon standard of care, especially for those harboring various oncogenic mutations associated with poor prognosis.
Treatment OutcomesIncorporating TUS into r/r AML treatment regimens could permit treatment of more patients, improvement in safety outcomes, enhancement of survival outcomes, and avoiding common first-line therapeutic failures.